Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Prostate Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Prostate Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Prostate Cancer 11/26/2008 - (DGNews)
    Aromatase Inhibitors, Androgen Deprivation Increase Risk of Bone Loss - (DGNews)
    Relationship Between Prostate Inflammation, Lower Urinary-Tract Symptoms Evident - (DGNews)
    TopAbstracts in Prostate Cancer 11/12/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Prostate Cancer

    Webcasts/CME archive

     Recent cases - Prostate Cancer
      Anejaculation as an Atypical Presentation of Prostate Cancer: A Case Report
      FDG PET-CT Demonstration of Metastatic Neuroendocrine Tumor of Prostate
      Ophthalmoplegia - An Unusual Manifestation of Metastatic Carcinoma of the Prostate
      Hypertrophic Osteoarthropathy as the Cause of a Super Scan of the Bone in a Patient with Prostate Cancer: A Case Report
      Giant Organ Confined Prostatic Adenocarcinoma: A Case Report

      Cases archive
        




      my personal edition > prostate cancer > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      FDA Approves Taxotere (Docetaxel) in Combination With Prednisone for Prostate Cancer Therapy

      BRIDGEWATER, NJ -- May 20, 2004 -- Aventis (NYSE: AVE) announced today that the U.S. Food and Drug Administration (FDA) has approved TaxotereŽ (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone-refractory) metastatic prostate cancer.

      The FDA approval is based on the final results of a landmark phase III clinical trial that met its primary endpoint of increasing survival in this patient population. The pivotal study, TAX 327, along with an additional study of Taxotere in this patient population, have been selected for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) annual meeting on Monday, June 7, in New Orleans, LA. A regulatory submission for Taxotere in prostate cancer is also pending with the European Agency for the Evaluation of Medicinal Products (EMEA).

      "This approval for Taxotere provides evidence that our drug can positively impact the lives of men around the world with this disease. In addition, this latest FDA action makes Taxotere the only drug approved for breast, lung and prostate cancer, three of the most prevalent cancers in the world today," said Frank Douglas, MD, PhD, Executive Vice President of Drug Innovation and Approval and a Member of the Board of Management at Aventis.

      About Prostate Cancer

      Prostate cancer ranks third worldwide in cancer incidence and sixth in cancer mortality among men. In the United States, more than 230,000 American men will be diagnosed with prostate cancer this year, and more than 29,900 will die of the disease.

      Current therapy for advanced prostate cancer is hormonal manipulation (i.e., blockage of androgen hormones like testosterone that would otherwise stimulate the growth of prostate cancer cells). However, the effects of this treatment typically last between 24 and 36 months, at which time patients may become refractory to hormonal therapy and be considered candidates for chemotherapy, such as Taxotere.

      About Taxotere

      Taxotere, a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially "freezing" the cell's internal skeleton, which is comprised of microtubules. Microtubules assemble and disassemble during a cell cycle. Taxotere promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing and resulting in cancer cell death.

      Taxotere is currently approved in the United States to treat patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, and patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin, who had not received prior chemotherapy. It also is approved for patients with unresectable locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy.

      Among patients receiving Taxotere the most common severe adverse events were low blood cell count, fatigue, diarrhea, and mouth and throat irritation. The most common non-severe side effects include hair loss, numbness, a tingling and/or burning sensation, rash, nail changes, nausea, vomiting, and muscle pain.

      Less common severe or potentially life threatening side effects include fluid retention, infections, and allergic reactions.

      Patients 65 years of age or older may experience some side effects more frequently. For more information about Taxotere, visit http://www.taxotere.com or see full prescribing information including boxed WARNINGS. For more information about ongoing clinical trials, please call 1-800-RxTrial or visit http://www.aventisoncology.com.


      SOURCE: Aventis



      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send